Tyra reports Q2 2026 results, sets September readout for dabogratinib bladder cancer trial

Tyra Biosciences reported second quarter 2026 results on August 4, 2026 and outlined near-term milestones for its lead candidate, oral dabogratinib, across three ongoing Phase 2 trials.

The company said it will host a conference call and webcast in September 2026 to report initial results from the SURF302 study, including safety results from more than 40 patients and efficacy from more than 20 patients in the aggregate at both QD dose levels.¹ SURF302 is testing dabogratinib in intermediate-risk non-muscle invasive bladder cancer, and is a Phase 2, multicenter, open-label clinical study evaluating the efficacy and safety of oral dabogratinib at two QD doses (50 mg and 60 mg) in participants with FGFR3-altered low-grade IR NMIBC.¹

In the achondroplasia program, BEACH301 has enrolled the safety sentinel cohort and cleared four dose levels with no notable safety events reported to date, and the Data Safety Monitoring Committee has authorized opening a fifth dose level to evaluate 0.625 mg/kg in the safety sentinel cohort.¹ As a result, initial results from the safety sentinel cohort, including 6-month annualized height velocity and safety data for dose levels 1-5 covering an aggregate of approximately 25 children, are now expected at the end of Q1 2027.¹

For the third trial in the "3x3" strategy, SURF303 is a Phase 2a/b study evaluating dabogratinib at 60 mg and 80 mg QD doses in low-grade upper tract urothelial carcinoma, with initial results expected in 2027.¹

On personnel, in June 2026 Tyra appointed Jonathan Day, MBBS, PhD, FFPM, FESC, as Executive Vice President, Clinical Development, to lead the company's development program and clinical strategy for oral dabogratinib in skeletal dysplasia conditions.¹

Financially, Tyra had cash, cash equivalents and marketable securities of $353.9 million as of June 30, 2026, which it said is expected to fund operations into the second half of 2028.¹ Separately, Tyra entered an amended sales agreement with TD Securities (USA) LLC in August 2026 allowing it to sell up to an additional $250.0 million of common stock through at-the-market offerings.¹